Claims 1, 4, 5, and 6 (death, blindness, cancer, permanent GI paralysis) lack peer-reviewed or clinical trial support. Claim 2 (semaglutide/Wegovy/Ozempic are GLP-1 analogues) is factually correct and supported by FDA records and clinical evidence. Claim 3 (manufacturing substrates) falls outside published scientific literature and into proprietary regulatory filings. The post's safety allegations are not substantiated by available PubMed or ClinicalTrials.gov data.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Urgent warning! Please see my review of the patent and productions methods of GLP-1 analogues on my rumble channel. The side effects may cost you your life!
Semaglutide, wegovy, Ozempic and so many more !
Cancer laced GLP-1 analogues are made using the following:
Human embryonic kidney cells, SV-40 monkey kidney cells, baby hamster kidneys, Human liver cells, genetically modified yeast.
Side …
Show full post caption
effects: Blindness, cancer, permanent paralyzation of Gastrointestinal function, depression, death, widespread inflammation and damage to organs like heart, liver, pancreas and gallbladder. https://rumble.com/v7982ew-cancer-laced-glp-1-patent.html
Show lessVideo transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.
Claim breakdown
6 claims“GLP-1 analogues may cause death.”
No PubMed abstracts or clinical trial data directly address mortality risk from GLP-1 analogues. The three completed/active Phase 3 trials identified (NCT01847313, NCT01681550, NCT03665350) focus on renal outcomes, hypoglycemia, and heart failure management—not mortality as a primary safety signal. Clinical trials for semaglutide (STEP, SUSTAIN series) and other GLP-1 agonists have established safety profiles with common GI side effects, but no published literature supports a specific death-risk claim.
“Semaglutide, Wegovy, and Ozempic are GLP-1 analogues.”
This is a straightforward factual claim supported by FDA approval records and clinical trial data. Semaglutide is a GLP-1 receptor agonist marketed as Ozempic (type 2 diabetes, FDA-approved 2017), Wegovy (chronic weight management, FDA-approved 2021), and Rybelsus (oral formulation). Clinical trial NCT06803888 and PeptIQ internal peptide profiles confirm this classification.
“GLP-1 analogues are made using human embryonic kidney cells, SV-40 monkey kidney cells, baby hamster kidneys, human liver cells, and genetically modified yeast.”
No peer-reviewed literature or clinical trial registry data were found describing the specific cellular substrates (HEK293, SV-40 monkey kidney, baby hamster kidney, hepatocytes, genetically modified yeast) used in semaglutide or other GLP-1 analogue manufacturing. This claim falls outside published scientific disclosure in PubMed and ClinicalTrials.gov. Manufacturing details are typically proprietary and documented in regulatory (FDA) filings, not peer-reviewed journals.
“Side effects of GLP-1 analogues include blindness.”
No PubMed abstracts or clinical trial data link GLP-1 analogues to blindness as a side effect. The identified trial (NCT03912623, spa treatment in type 2 diabetes) is unrelated to GLP-1 safety profiles. Established adverse event monitoring from STEP and SUSTAIN trials does not report blindness or vision loss.
“Side effects of GLP-1 analogues include cancer.”
No PubMed abstracts or clinical trials directly link GLP-1 analogues to cancer risk. The two identified trials (NCT05949281 on colchicine in type 1 diabetes; NCT07006272 on closed-loop therapy) do not address GLP-1 oncological safety. Large Phase 3 cardiovascular and renal outcome trials (SUSTAIN-6, LEADER) have not raised cancer as a signal, though comprehensive oncology meta-analyses specific to GLP-1 use were not retrieved in this search.
“Side effects of GLP-1 analogues include permanent paralyzation of gastrointestinal function.”
No peer-reviewed literature or registered clinical trials were found describing permanent paralysis of gastrointestinal function from GLP-1 analogues. While GLP-1 agonists are known to cause transient GI effects (nausea, vomiting, constipation, delayed gastric emptying), these are typically reversible and documented in Phase 3 trials. No mechanistic or clinical evidence supports a permanent paralysis claim.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error